Nurix Therapeutics NRIX 深 沪
已收盘 12-19 16:00:00 美东时间
18.535
+0.525
+2.92%
华盛通- 最 高22.4999
- 今 开18.00
- 成交量 122.40万股
- 最 低 16.02
- 昨 收 18.01
- 总市值 8.70亿
- 52周最高 22.4999
- 市盈率 静 --
- 换手率 2.61%
- 52周最低 8.18
- 委 比 -79.59%
- 总股本 4695.02万
- 历史最高 52.38
- 量 比 0.77
- 振 幅 35.98%
- 历史最低 1.10
- 每 手 1
- 风险率 3.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nurix三季度业绩不及预期
美股周五早盘，专注于靶向蛋白降解（TPD）疗法的临床阶段生物制药公司Nurix Therapeutics（NRIX）股价下跌7.5%，此前该公司公布第三季度GAAP每股亏损1.03美元，较预期低0.11美元；营收790万美元，低于预期433万美元。 第三季度内，NRIX公司持有4.288亿美元现金及等价物，较2024年11月的6.096亿美元有所下降。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
10-10 23:03
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics granted inducement awards, including stock options (97,400 shares) and RSUs (66,750), to 17 new employees on June 10, 2025, under its 2024 plan, approved by its Compensation Committee and in accordance with Nasdaq Listing Rule 5635(c)(4).
06-13 20:01
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Nurix Therapeutics announces positive Phase 1 data for bexobrutideg in CLL and WM patients, with an 80.9% ORR in CLL and 84.2% in WM, showing deepening responses over time. The treatment was well-tolerated with no new safety signals. Nurix plans to initiate pivotal trials in 2025 and will discuss data at EHA2025.
06-12 11:00
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Nurix Therapeutics将于6月12日举办网络会议，讨论其药物bexobrutideg (NX-5948)在欧洲血液学会年会上展示的新临床数据。该药物为一种BTK降解剂，在治疗复发难治性 CLL 和 Waldenström 巨球蛋白血症的1期试验中表现出快速、持续的临床反应，且安全性良好。会议将通过公司投资者页面网络直播，电话接入号码为877-346-6112（美国）或1-848-280-6350（国际）。回放将在公司网站存档约30天。
06-06 11:00
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
<p>Sanofi has purchased Nurix's STAT6 program for an additional $15 million, bringing total payments to $127 million. The program includes NX-3911, an oral STAT6 degrader targeting type 2 inflammation in diseases like atopic dermatitis and asthma. Nurix could earn up to $465 million in milestones plus royalties and has the option to co-develop in the U.S.</p>
06-02 11:00
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Nurix Therapeutics executives will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, to discuss their targeted protein degradation medicines for cancer and inflammatory diseases.
05-28 11:00
Analyst Ratings For Nurix Therapeutics
Throughout the last three months, 11 analysts have evaluated Nurix Therapeutics (NASDAQ:NRIX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding ...
2024-09-05 03:01
